BGI Group

BGI Group, formerly Beijing Genomics Institute, is a Chinese genomics company with headquarters in Yantian District, Shenzhen. The company was originally formed in 1999 as a genetics research center to participate in the Human Genome Project.[3][4] It also sequences the genomes of other animals, plants and microorganisms.[5]

BGI Group
FormerlyBeijing Genomics Institute
TypePrivate
IndustryOmics
Genome sequencing
Biotechnology
FoundedSeptember 9, 1999 (1999-09-09)
FounderWang Jian
Yu Jun
Yang Huanming
Liu Siqi
HeadquartersShenzhen, Guangdong, China
Number of locations
A global presence in more than 100 countries and regions[1][2]
Area served
Worldwide
Key people
Wang Jian (Co-Founder and Chairman)
ProductsDNBseq Platform (next-generation sequencing platform), RT-PCR tests for the detection of the SARS CoV-2 virus and its mutations. Huo-Yan integrated laboratory solution. The NIFTY Test (a non-invasive prenatal test)
BrandsDNBseq, NIFTY, Huafeiran, Huachangkang, Huajianwei, Huachangan, Huafanan, SeqHPV, PMseq
RevenueIncrease $251 million (2016)[2]
Increase $51.7 million (2016)[2]
OwnerWang Jian
Number of employees
~ 10,000 (worldwide)
DivisionsBGI China (Mainland)
BGI Asia Pacific
BGI Americas
BGI Europe (Europe and Africa)
Subsidiaries
Websitegenomics.cn

BGI has transformed from a small research institute, notable for decoding the DNA of pandas and rice plants, into a diversified company active in animal cloning, health testing, and contract research.[6][7][8] BGI's earlier research was continued by the Beijing Institute of Genomics, Chinese Academy of Sciences.[9] BGI Research, the group's nonprofit division, works with the Institute of Genomics and operates the China National GeneBank under a contract with the Chinese government.[10][11] BGI Genomics, a subsidiary, was listed on the Shenzhen Stock Exchange in 2017.

In 2021, details came to light about multiple controversies involving the BGI Group. These controversies include alleged collaboration with the People's Liberation Army (PLA) and use of genetic data from prenatal tests.[12] BGI denied that it shares prenatal genetics data with the PLA.[13]

History

Wang Jian, Yu Jun, Yang Huanming and Liu Siqi created BGI, originally named Beijing Genomics Institute, in September 1999,[14] in Beijing, China as a non-governmental independent research institute in order to participate in the Human Genome Project as China's representative.[15][16] After the project was completed, funding dried up, after which BGI moved to Hangzhou in exchange for funding from the Hangzhou Municipal Government. In 2002, BGI sequenced the rice genome, which was a cover story in the journal Science. In 2003 BGI decoded the SARS virus genome and created a kit for detection of the virus.[17] In 2003, the Chinese Academy of Sciences founded the Beijing Institute of Genomics in cooperation with BGI, with Yang Huanming as its first director. BGI Hangzhou and the Zhejiang University also founded a new research institute, the James D. Watson Institute of Genome Sciences, Zhejiang University.[18]: 39 

In 2007, BGI broke away from the Chinese Academy of Sciences and relocated to Shenzhen.[19][10] Yu Jun left BGI at this time purportedly selling his stake to the other 3 founders for a nominal sum.[5] In 2008, BGI published the first human genome of an Asian individual.[15][20]

In 2010, BGI bought 128 Illumina HiSeq 2000 gene-sequencing machines,[3][15] which was backed by US$1.5 billion in "collaborative funds" over the next 10 years from the state lender China Development Bank.[5][21][22] By the end of the year, they reportedly had a budget of $30 million.[23] In 2010, BGI Americas was established with its main office in Cambridge, Massachusetts, US, and BGI Europe was established in Copenhagen, Denmark.[24][25] By 2018, BGI opened offices and laboratories in Seattle and San Jose in US,[3] and London in the UK, as well were founded BGI Asia Pacific with offices in Hong Kong, Kobe (Japan), Bangkok (Thailand), Laos, Singapore, Brisbane (Australia) and many others.[26][27]

In 2011, BGI reported it employed 4,000 scientists and technicians,[28] and had a $192 million in revenue.[5] BGI did the genome sequencing for the deadly 2011 Germany E. coli O104:H4 outbreak in three days and released it under an open license.[29] Since 2012, it has started to commercialize its services, having investments from China Life Insurance Company, CITIC Group's Goldstone Investment, Jack Ma's Yunfeng Capital, and SoftBank China Capital.[30] That year they also launched their own scientific journal, GigaScience,[31] partnering with BioMed Central to publish data-heavy life science papers.[32] A new partnership was subsequently formed between the GigaScience Press department of BGI and Oxford University Press and since 2017 GigaScience has been co-published with the Oxford University Press.[33][34]

In 2013, BGI bought Complete Genomics of Mountain View, California, a major supplier of DNA sequencing technology, for US$118 million, after gaining approval from the Committee on Foreign Investment in the United States.[5][29][35] Complete Genomics is a US-based subsidiary of MGI, MGI was a subsidiary of BGI before it was spun out and listed on the Shanghai stock exchange in 2022.[36]

In 2015, BGI signed a collaboration with the Zhongshan Hospital' Center for Clinical Precision Medicine in Shanghai, opened in May 2015 with a budget of ¥100 million. They are reportedly being involved as a sequencing institution in China's US$9.2-billion research project for medical care which will last for 15 years.[3][37] In May 2017, was announced formation of West Coast Innovation Center, co-located in Seattle and San Jose, on the first location planned to work on precision medicine and feature collaborations with University of Washington, the Allen Institute for Brain Science, the Bill & Melinda Gates Foundation, and Washington State University, while on the second's already existing laboratory with 100 employees to develop the next-generation sequencing technologies.[3] In May 2018, reached an agreement with Mount Sinai Hospital (Toronto), Canada, for first installation of BGISEQ platforms in North America.[38]

BGI Genomics, a listed subsidiary of the group[39] made an initial public offering in July 2017 at Shenzhen Stock Exchange.[10] In 2018, the BGI was reportedly 85.3% owned by Wang Jian, and the group owns 42.4% of its main unit BGI Genomics.[40]

In 2019, it was reported that a BGI subsidiary, Forensic Genomics International, had created a WeChat-enabled database of genetic profiles of people across the country.[41][42][43][44][45] In July 2020, it was reported that BGI returned a Paycheck Protection Program loan following media scrutiny.[46]

In 2021, state-owned enterprises of State Development and Investment Corporation and China Merchants Group took ownership stakes in BGI Genomics.[47]

U.S. sanctions
Further information: United States sanctions against China

In July 2020, the United States Department of Commerce's Bureau of Industry and Security placed two BGI subsidiaries on its Entity List for assisting in alleged human rights abuses due to its genetic analysis work in Xinjiang.[48][49]

In March 2023, the United States Department of Commerce added BGI Research and BGI Tech Solutions (Hongkong) to the Entity List over allegations of surveillance and repression of ethnic minorities.[50]

Projects

COVID-19

In January 2020, BGI Genomics announced its real-time fluorescent RT-PCR kit that helps in identification of SARS-CoV-2 virus that causes COVID-19. This was subsequently verified and authorized for use in 14 countries and regions, including emergency use listing by the World Health Organization.[51] BGI Genomics reported that by April 2021 the RT-PCR kits had been distributed to more than 180 countries and regions. BGI also developed biosafety level 2 high-throughput nucleic acid detection laboratories, named Huo-Yan laboratories.[34][52]

In the first half of 2020, BGI Group offered to help the state of California set up COVID-19 testing labs at cost. The government of California rejected the offer due to geopolitical concerns, but Santa Clara County did buy COVID-19 test kits and equipment from BGI.[53]

On August 25, 2020, Reuters reported that about 3,700 people in Sweden were told in error that they had the coronavirus due to a fault in a COVID-19 testing kit from BGI Genomics.[54] Despite being the 5th test to be given WHO Emergency Use Listing,[55] and getting top marks in sensitivity tests in a Dutch study independently validating commercially available tests.[56] BGI Genomics defended the product, blaming differences in thresholds used between labs looking at very low levels of the virus.[57]

Bioinformatics technology

The annual budget for the computer center was US$9 million.[23] In the same year, BGI's computational biologists developed the first successful algorithm, based on graph theory, for aligning billions of 25 to 75-base pair strings produced by next-generation sequencers, specifically Illumina's Genome Analyzer, during de novo sequencing.[58]

SOAPdenovo is part of "Short Oligonucleotide Analysis Package" (SOAP), a suite of tools developed by BGI for de novo assembly of human-sized genomes, alignment, SNP detection, resequencing, indel finding, and structural variation analysis. Built for the Illumina sequencers' short reads, SOAPdenovo has been used to assemble multiple human genomes[59][60][61] (identifying an eight kilobase insertion not detected by mapping to the human reference genome[62]) and animals, like the giant panda.[63]

Up until 2015, BGI had released BGISEQ-100, based on Thermo Fisher Scientific's Ion Torrent device, and BGISEQ-1000, for both of which received an approval from the CFDA for a NIFTY (Non-invasive Fetal Trisomy Test) prenatal test.</ref>[64] In October 2015, BGI launched BGISEQ-500,[65] a larger desktop sequencing system. It reportedly received more than 500 orders for the system and run over 112,000 tests until late 2016.[64] The China National GeneBank, opened by BGI and Chinese Government in September 2016,[66] has 150 instruments of the system.[64] The BGISEQ-500 was developed as a sequencing platform capable of competing with Illumina's platforms.[67] In November 2016, BGI launched BGISEQ-50, a miniature version of desktop sequencer.[68] In 2017, BGI began offering WGS for $600.[3] In September 2022, MGI launched DNBSeq-G99, a new ultra-high-speed, mid-to-low throughput sequencer.[69]

In 2021, BGI developed Stereo-seq, its genome wide Spatial transcriptomics technology and released the first research findings from a consortium of scientific users of the technology in 2022.[70][71] In 2022, BGI-Research and University of Chinese Academy of Sciences together with scientists globally, used sequencing technologies to undertake single cell sequencing to expand the understanding of early human embryonic development, to complete the first whole-body cell atlas of a non-human primate, to complete the world's first body-wide single cell transcriptome atlas of pigs, and to study the brains of ants to explain for the first time how the social division of labor within ant colonies is determined by functional specialization of their brains at cellular levels.[72][73]

In 2019, competitor Illumina, Inc. filed multiple patent infringement lawsuits against BGI.[74][75] In response, BGI has filed patent infringement lawsuits against Illumina alleging violations of federal antitrust and California unfair competition laws.[76] In May 2022 a US court ordered Illumina to pay US$333.8 million to BGI Group after finding that Illumina's DNA-sequencing systems infringed two of BGI's patents.[77] The ruling also stated Illumina infringed the patents wilfully, and that three patents it had accused BGI's Complete Genomics subsidiary of infringing were invalid.[78] In July 2022 Illumina and MGI Tech Co. and Complete Genomics, settled US suits on DNA-sequencing technology, with Illumina agreeing to pay $325 million to settle all US litigation. As part of the settlement Illumina will receive a license to the BGI affiliates' patents, and both companies agreed to not sue each other for patent or antitrust violations in the United States for three years.[79]

Collaboration with the People's Liberation Army
See also: Military-civil fusion

In January 2021, Reuters reported that BGI has worked with the People's Liberation Army (PLA) and affiliated institutions such as the National University of Defense Technology on efforts to enhance soldiers' strength and other projects.[80] In July 2021, Reuters reported that BGI developed a prenatal test, with the assistance of the People's Liberation Army, which is also used for genetic data collection.[81][12] In an interview with the South China Morning Post, a BGI representative denied the Reuters report.[13] The South China Morning Post stated that BGI published papers with the People's Liberation Army General Hospital and the Army Medical University, explaining in the article that in China "many top-notch hospitals are affiliated with the military."[13] BGI further stated "All NIPT data collected overseas are stored in BGI's laboratory in Hong Kong and are destroyed after five years, as stipulated by General Data Protection Regulation (GDPR)".[82] BGI also stated "BGI has never been asked to provide, nor has it provided data from its NIFTY tests to Chinese authorities for national security or national defense security purposes."[81]

In response to the Reuters report, a German privacy regulator launched a probe of a German company's use of BGI's prenatal genetic tests.[83] In August 2021, the UK announced a registration requirement with the Medicines and Healthcare products Regulatory Agency for BGI's prenatal tests.[84] Regulators in Australia, Estonia, Canada, and Poland also raised concerns as did the U.S. National Counterintelligence and Security Center.[85][86][87]

In November 2021, Reuters reported that a University of Copenhagen professor, Guojie Zhang, who was also employed by BGI was developing drugs for the PLA to assist soldiers with managing altitude sickness.[88] BGI stated that the study "was not carried out for military purposes."[88] On December 1, 2021, the University of Copenhagen commented on the Reuters report.[89]

In October 2022, the United States Department of Defense added BGI Genomics Co, a listed subsidiary, to a list of "Chinese military companies" operating in the U.S.[90][91]

See also

References
  1. Kon, James (18 March 2020). "MoH receives COVID-19 detection kits". Borneo Bulletin.
  2. "BGI Genomics Raises $81M in IPO". Genetic Engineering & Biotechnology News. 17 July 2017. Retrieved 2 December 2018.
  3. Megan Molteni (18 May 2017). "A Chinese Genome Giant Sets Its Sights on the Ultimate Sequencer". Wired. Retrieved 2 December 2018.
  4. Aaron Saenz (11 November 2010). "BGI – China's Genomics Center Has A Hand in Everything". Singularity Hub. Singularity University. Retrieved 2 December 2018.
  5. Shu-Ching Jean Chen (2 September 2013). "Genomic Dreams Coming True in China". Forbes Asia. Retrieved 27 October 2014.
  6. "China's BGI says it can sequence a genome for just $100". MIT Technology Review. Retrieved 2022-01-30.
  7. He, Ximiao; Wang, Jun (2007). "Bgi-Ris V2". Plant Bioinformatics. Methods in Molecular Biology. Vol. 406. pp. 275–299. doi:10.1007/978-1-59745-535-0_13. ISBN 978-1-58829-653-5. ISSN 1064-3745. PMID 18287698.
  8. "China cloning on an 'industrial scale'". BBC News. 2014-01-14. Retrieved 2022-01-29.
  9. Cyranoski, David (2010). "Chinese bioscience: The sequence factory". Nature. 464 (7285): 22–24. doi:10.1038/464022a. ISSN 0028-0836. PMC 7095434. PMID 20203579.
  10. Campbell, Matthew; Lyu, Dong (13 November 2019). "China's Genetics Giant Wants to Tailor Medicine to Your DNA". Bloomberg Businessweek. Retrieved 2022-01-30.
  11. "COVID opens new doors for China's gene giant". mint. 2020-08-05. Retrieved 2022-01-30.
  12. Needham, Kirsty; Baldwin, Clare (7 July 2021). "China's gene giant harvests data from millions of women". Reuters. Archived from the original on 10 July 2021. Retrieved 10 July 2021.
  13. Deng, Iris (July 12, 2021). "BGI denies it shared genetic data of pregnant women with China's military and vows to continue overseas push". South China Morning Post. Retrieved July 14, 2021.
  14. Yu J (2007). "Biotechnology Research in China". In Jakobson L (ed.). Innovation with Chinese Characteristics: High-Tech Research in China. London: Palgrave Macmillan UK. pp. 134–165. doi:10.1057/9780230591929_5. ISBN 978-0-230-59192-9.
  15. Kevin Davies, (27 September 2011) The Bedrock of BGI: Huanming Yang Bio-IT World, Retrieved 14 January 2014
  16. The dragon's DNA, Jun 17th 2010, The Economist
  17. Qin, E'de; et al. (2003-05-01). "A Genome Sequence of Novel SARS-CoV Isolates: the Genotype, GD-Ins29, Leads to a Hypothesis of Viral Transmission in South China". Genomics, Proteomics & Bioinformatics. 1 (2): 101–107. doi:10.1016/S1672-0229(03)01014-3. ISSN 1672-0229. PMC 5172408. PMID 15626340.
  18. Sullivan, Lawrence R.; Liu-Sullivan, Nancy Y. (2015-03-19). Historical Dictionary of Science and Technology in Modern China. Rowman & Littlefield. ISBN 978-0-8108-7855-6.
  19. Wang, Kai; Shen, Xiaobai; Williams, Robin (2021-07-03). "Sequencing BGI: the evolution of expertise and research organisation in the world's leading gene sequencing facility". New Genetics and Society. 40 (3): 305–330. doi:10.1080/14636778.2020.1843148. ISSN 1463-6778.
  20. Ye, Jia (2008) An Interview with a Leader in Genomics — Beijing Genomics Institute Archived 2014-01-16 at the Wayback Machine Asia Biotech, Retrieved 14b January 2013
  21. "BGI to Receive $1.5B in 'Collaborative Funds' Over 10 Years from China Development Bank | In Sequence | Sequencing | GenomeWeb". 12 January 2010. Retrieved 29 March 2010.
  22. Fox, J.; Kling, J. (2010). "Chinese institute makes bold sequencing play". Nature Biotechnology. 28 (3): 189–191. doi:10.1038/nbt0310-189c. PMC 7097335. PMID 20212469. S2CID 205266392.
  23. Petsko, G. A. (2010). "Rising in the East". Genome Biology. 11 (1): 102. doi:10.1186/gb-2010-11-1-102. PMC 2847708. PMID 20156314. S2CID 7008023.
  24. "BGI Expands Into Denmark with Plans for $10M Headquarters, Staff of 150". Genomeweb. 2010-05-19. Retrieved 2022-09-20.
  25. "BGI Opens Branches in US, Denmark; to Invest $10M in Copenhagen Site During First Year". Genomeweb. 2010-05-25. Retrieved 2022-09-20.
  26. "BGI Asia Pacific". BGI. Retrieved 3 December 2018.
  27. "Offices and Laboratories". BGI. Retrieved 3 December 2018.
  28. Lone Frank, High-Quality DNA, Apr 24, 2011, The Daily Beast
  29. Specter, Michael (2013-12-30). "The Gene Factory". The New Yorker. Retrieved 2022-10-23.
  30. Wang Luyao; Han Wei (19 July 2018). "Genome Giant Seeks $1 Billion for Equipment Unit for Potential IPO". Caixin. Retrieved 3 December 2018.
  31. "Large and linked in scientific publishing the launch of big data journal GigaScience". EurekAlert!. Retrieved 2019-06-17.
  32. Pollack, Andrew (2011-11-30). "DNA Sequencing Caught in Deluge of Data". The New York Times. ISSN 0362-4331. Retrieved 2019-06-17.
  33. "GigaScience. - NLM Catalog - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2022-02-05.
  34. LeMieux, Julianna; PhD (2020-02-12). "BGI's Coronavirus Response? Build a Lab in Wuhan". GEN - Genetic Engineering and Biotechnology News. Retrieved 2022-01-27.
  35. "China's Biotechnology Development: The Role of US and Other Foreign Engagement" (PDF). United States-China Economic and Security Review Commission. February 14, 2019. Retrieved October 23, 2022.
  36. Smyth, Jamie; Sevastopulo, Demetri (18 April 2023). "Chinese genetics company targets US despite political tensions". Financial Times. Retrieved 2023-04-18.
  37. David Cyranoski (6 January 2016). "China embraces precision medicine on a massive scale". Nature. Retrieved 2 December 2018.
  38. Rebecca Robbins; Kate Sheridan (26 October 2018). "A Chinese company unveils a powerful new sequencer. But can it compete in the U.S.?". Stat. Retrieved 3 December 2018.
  39. "Special Report: COVID opens new doors for China's gene giant". Reuters. 2020-08-05. Retrieved 2022-10-23.
  40. "MGI raise $518M in Shanghai IPO, shares jump 14.71% on debut". Bioworld. Retrieved 2022-09-14.
  41. Moreau, Yves (2019-12-03). "Crack down on genomic surveillance". Nature. 576 (7785): 36–38. Bibcode:2019Natur.576...36M. doi:10.1038/d41586-019-03687-x. PMID 31796907. S2CID 208621060.
  42. "BGI officially enters Urumqi High-tech Zone". www.uhdz.gov.cn (in Chinese). 2016-07-27. Archived from the original on 2019-12-07. Retrieved 2019-12-07.
  43. Cyranoski, David (25 May 2017). "China expands DNA data grab in troubled western region". Nature. 545 (7655): 395–396. Bibcode:2017Natur.545..395C. doi:10.1038/545395a. ISSN 0028-0836. PMID 28541335.
  44. Wee, Sui-Lee; Mozur, Paul (2019-12-03). "China Uses DNA to Map Faces, With Help From the West". The New York Times. ISSN 0362-4331. Retrieved 2020-02-15.
  45. Allen-Ebrahimian, Bethany; Dorfman, Zach (June 3, 2020). "Chinese coronavirus test maker agreed to build a Xinjiang gene bank". Axios. Archived from the original on June 3, 2020. Retrieved June 3, 2020.
  46. Allen-Ebrahimian, Bethany (July 20, 2020). "Chinese biotech giant's U.S. subsidiary returns PPP loan after Axios story". Axios. Retrieved July 20, 2020.
  47. Needham, Kirsty (2021-02-22). "Chinese state fund invests in gene firm BGI". Reuters. Retrieved 2022-10-23.
  48. Basu, Zachary (July 20, 2020). "U.S. blacklists Chinese companies tied to Xinjiang gene bank project". Axios. Retrieved July 20, 2020.
  49. "Commerce Department Adds Eleven Chinese Entities Implicated in Human Rights Abuses in Xinjiang to the Entity List". U.S. Department of Commerce. 2020-07-20. Archived from the original on 2020-07-21. Retrieved 2020-07-20.
  50. Alper, Alexandra; Shepardson, David (2023-03-02). "U.S. adds units of China's BGI, Inspur to trade blacklist". Reuters. Retrieved 2023-03-02.
  51. Ajohney (2020-03-19). "Covid-19: BGI launches RT-PCR SARS-CoV-2 test for clinical use in US". Medical Device Network. Retrieved 2022-01-31.
  52. Burdin, Peter (2021-11-16). "Africa's world-leading pandemic response". New African. Retrieved 2022-01-27.
  53. "California rejected Chinese company's push to help with coronavirus testing. Was that the right move?". Washington Post. Retrieved 10 March 2023.
  54. Johnson, Simon (25 August 2020). "Thousands of Swedes got false positive COVID-19 result due to test kit fault". Reuters. Archived from the original on 28 August 2020. Retrieved 27 August 2020.
  55. World Health Organisation. "WHO Emergency Use Listing for In vitro diagnostics (IVDs) Detecting SARS-CoV-2" (PDF).
  56. "Chinese Covid-19 test kit outstrips alternatives in Dutch study". South China Morning Post. 2020-05-20. Retrieved 2020-11-01.
  57. "China's BGI defends COVID-19 test kit after Swedish criticism". Reuters. 2020-08-26. Retrieved 2020-11-01.
  58. "To Start Building 'Human Pan-Genome,' BGI De Novo Assembles Two Genomes from Illumina Data | In Sequence | Sequencing | GenomeWeb". 8 December 2009. Retrieved 29 March 2010.
  59. Li, R.; Zhu, H.; Ruan, J.; Qian, W.; Fang, X.; Shi, Z.; Li, Y.; Li, S.; Shan, G.; Kristiansen, K.; Li, S.; Yang, H.; Wang, J.; Wang, J. (2009). "De novo assembly of human genomes with massively parallel short read sequencing". Genome Research. 20 (2): 265–272. doi:10.1101/gr.097261.109. PMC 2813482. PMID 20019144.
  60. Rasmussen, M.; Li, Y.; Lindgreen, S.; Pedersen, J. S.; Albrechtsen, A.; Moltke, I.; Metspalu, M.; Metspalu, E.; Kivisild, T.; Gupta, R.; Bertalan, M.; Nielsen, K.; Gilbert, M. T. P.; Wang, Y.; Raghavan, M.; Campos, P. F.; Kamp, H. M.; Wilson, A. S.; Gledhill, A.; Tridico, S.; Bunce, M.; Lorenzen, E. D.; Binladen, J.; Guo, X.; Zhao, J.; Zhang, X.; Zhang, H.; Li, Z.; Chen, M.; Orlando, L. (2010). "Ancient human genome sequence of an extinct Palaeo-Eskimo". Nature. 463 (7282): 757–762. Bibcode:2010Natur.463..757R. doi:10.1038/nature08835. PMC 3951495. PMID 20148029. S2CID 4423505.
  61. Wang, J.; Wang, W.; Li, R.; Li, Y.; Tian, G.; Goodman, L.; Fan, W.; Zhang, J.; Li, J.; Zhang, J.; Guo, Y.; Feng, B.; Li, H.; Lu, Y.; Fang, X.; Liang, H.; Du, Z.; Li, D.; Zhao, Y.; Hu, Y.; Yang, Z.; Zheng, H.; Hellmann, I.; Inouye, M.; Pool, J.; Yi, X.; Zhao, J.; Duan, J.; Zhou, Y.; Qin, J. (2008). "The diploid genome sequence of an Asian individual". Nature. 456 (7218): 60–65. Bibcode:2008Natur.456...60W. doi:10.1038/nature07484. PMC 2716080. PMID 18987735. S2CID 4397887.
  62. "BGI Uses New Short-Read Algorithm to Assemble Panda Genome as Proof of Concept for Human Genome | BioInform | Informatics | GenomeWeb". 12 June 2009. Retrieved 28 March 2010.
  63. Li, R.; Fan, W.; Tian, G.; Zhu, H.; He, L.; Cai, J.; Huang, Q.; Cai, Q.; Li, B.; Bai, Y.; Zhang, Z.; Zhang, Y.; Wang, W.; Li, J.; Wei, F.; Li, H.; Jian, M.; Li, J.; Zhang, Z.; Nielsen, R.; Li, D.; Gu, W.; Yang, Z.; Xuan, Z.; Ryder, O. A.; Leung, F. C. C.; Zhou, Y.; Cao, J.; Sun, X.; et al. (2009). "The sequence and de novo assembly of the giant panda genome". Nature. 463 (7279): 311–317. Bibcode:2010Natur.463..311L. doi:10.1038/nature08696. PMC 3951497. PMID 20010809. S2CID 4317858.
  64. "BGI Launches New Desktop Sequencer in China, Registers Larger Version With CFDA". 360Dx. GenomeWeb. 11 November 2016. Retrieved 2 December 2018.
  65. Julia Karow (26 October 2015). "BGI Launches Desktop Sequencer in China; Plans to Register Platform With CFDA". GenomeWeb. Retrieved 2 December 2018.
  66. Monica Heger (21 September 2016). "China National GeneBank Opens With Investments From BGI, Government". GenomeWeb. Retrieved 2 December 2018.
  67. "BGI Retools Complete Genomics Technology for Its New High-Throughput Benchtop Sequencer". Bio-ITWorld. Cambridge Healthtech Institute. 28 October 2015. Retrieved 2 December 2018.
  68. Monica Heger (26 October 2018). "BGI Launches New Sequencer as Customers Report Data From Earlier Instruments". GenomeWeb. Retrieved 2 December 2018.
  69. "MGI Tech Launches New Ultra-High-Speed, Mid-to-Low Throughput Sequencer". Pubs - GenomeWeb. 27 September 2022. Retrieved 2022-09-27.
  70. Marx, Vivien (2021-01-06). "Method of the Year: spatially resolved transcriptomics". Nature. 18 (1): 9–14. doi:10.1038/s41592-020-01033-y. ISSN 1548-7105. PMID 33408395. S2CID 230817551.
  71. "SpatioTemporal Omics consortium: Cell Press". www.cell.com. Retrieved 2022-11-09.
  72. Mazid, Md. Abdul; et al. (12 May 2022). "Rolling back human pluripotent stem cells to an eight-cell embryo-like stage". Nature. 605 (7909): 315–324. Bibcode:2022Natur.605..315M. doi:10.1038/s41586-022-04625-0. ISSN 1476-4687. PMID 35314832. S2CID 247598940.
  73. Li, Qiye; Wang, Mingyue; Zhang, Pei; Liu, Yang; Guo, Qunfei; Zhu, Yuanzhen; Wen, Tinggang; Dai, Xueqin; Zhang, Xiafang; Nagel, Manuel; Dethlefsen, Bjarke Hamberg; Xie, Nianxia; Zhao, Jie; Jiang, Wei; Han, Lei; Wu, Liang; Zhong, Wenjiang; Wang, Zhifeng; Wei, Xiaoyu; Dai, Wei; Liu, Longqi; Xu, Xun; Lu, Haorong; Yang, Huanming; Wang, Jian; Boomsma, Jacobus J.; Liu, Chuanyu; Zhang, Guojie; Liu, Weiwei (16 June 2022). "A single-cell transcriptomic atlas tracking the neural basis of division of labour in an ant superorganism". Nature Ecology & Evolution. 6 (8): 1191–1204. doi:10.1038/s41559-022-01784-1. ISSN 2397-334X. PMC 9349048. PMID 35711063.
  74. Needham, Kirsty (May 14, 2020). "China's BGI gets Australian foothold through mass coronavirus test delivery". Reuters. Retrieved June 3, 2020.
  75. "Illumina Nears Win In Bid To Block BGI's DNA Product Sales". Law360. May 11, 2020. Retrieved June 3, 2020.
  76. "BGI Sues Illumina for Antitrust Violation, Claims Firm Obtained Sequencing Patents Through Fraud". GenomeWeb. 11 January 2021. Retrieved 2021-01-13.
  77. "Illumina Owes BGI $333.8 Million Over Gene-Sequencer Patents (2)". news.bloomberglaw.com. Retrieved 2022-05-17.
  78. Brittain, Blake (2022-05-07). "Illumina ordered to pay BGI subsidiary $333 million in DNA-sequencing patent case". Reuters. Retrieved 2022-05-17.
  79. Brittain, Blake (2022-07-14). "BGI Group units, Illumina settle U.S. lawsuits over DNA sequencing". Reuters. Retrieved 2022-10-05.
  80. Needham, Kirsty (2021-01-30). "China gene firm providing worldwide COVID tests worked with Chinese military". Reuters. Retrieved 2021-01-30.
  81. Needham, Kirsty; Baldwin, Clare (July 7, 2021). "Prenatal test developed with Chinese military stores gene data". Reuters. Retrieved July 7, 2021.
  82. Zhang, Adrianna (July 16, 2021). "Genetic Data Collection by Chinese Company Poses Global Policy Challenge, Experts Say". Voice of America. Retrieved July 19, 2021.
  83. "German privacy body probes German lab's use of BGI prenatal tests". Reuters. July 14, 2021. Retrieved July 14, 2021.
  84. "Britain says China's BGI must register prenatal tests by Sept 1". Reuters. August 5, 2021. Retrieved August 9, 2021.
  85. Baldwin, Clare; Needham, Kirsty (September 7, 2021). "BGI prenatal gene test under scrutiny for Chinese military links". Reuters. Retrieved September 7, 2021.
  86. Plucinska, Joanna (September 22, 2021). "Polish gene project moves to drop Chinese tech on data concerns". Reuters. Retrieved September 27, 2021.
  87. Barnes, Julian E. (2021-10-22). "U.S. Warns of Efforts by China to Collect Genetic Data". The New York Times. ISSN 0362-4331. Retrieved 2021-10-23.
  88. Needham, Kirsty; Jacobsen, Stine (2021-11-18). "Monkey-brain study with link to China's military roils top European university". Reuters. Retrieved 2021-11-20.
  89. "Comment on Reuters report". Institut Biologisk. 2021-12-01. Retrieved 2022-08-18.
  90. Singh, Kanishka (2022-10-08). "U.S. widens investment ban to China's BGI Genomics, drone maker DJI". Reuters. Retrieved 2022-10-19.
  91. "DOD Releases List of People's Republic of China (PRC) Military Companies in Accordance With Section 1260H of the National Defense Authorization Act for Fiscal Year 2021". U.S. Department of Defense. 2022-10-05. Retrieved 2022-10-05.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.